Maegim한국어

대성미생물

036480KOSDAQSector: Pharma & Biotech
₩6,450▼ 0.46%Market cap ₩24.5BAs of Jul 21, 2026 close · updated once daily
A
Grade A65.1 ptsTop 21% of 2,523 stocks
Financial strength
57.4
Growth momentum
69.7
Price attractiveness
70.7

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

57.4
How much debt does it carry relative to equity?
Debt-to-equity ratio
63.7%
✗ Below median · Top 59.1% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
295.8%
✓ Above median · Top 34.3% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
2.7%
✓ Above median · Top 38.1% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
1.7%
✓ Above median · Top 38.8% in sector
Sector median -4.5%

Source filing: annual report (separate) — view original ↗

2

Growth momentum

69.7
How much did revenue grow in a year?
Revenue growth (YoY)
9.2%
✓ Above median · Top 40.4% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
0.6%
✗ Below median · Top 66.2% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
146.0%
✓ Above median · Top 10.5% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
318.1%
✓ Above median · Top 4% in sector
Sector median 3.5%

Source filing: annual report (separate) — view original ↗

3

Price attractiveness

70.7
Is the price expensive relative to earnings?
P/E (price-to-earnings)
41.0x
✓ Above median · Top 34.8% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
0.69x
✓ Above median · Top 23.8% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15